Why Hormone Therapy Remains Controversial — and Misunderstood
Few topics in women's health carry as much confusion as menopausal hormone therapy (MHT), sometimes still referred to as HRT. Decades of shifting guidance, headlines that oversimplified complex data, and genuine ongoing scientific debate have left many women uncertain about what the evidence actually says. Understanding that complexity — rather than flattening it into a simple yes or no — is the first step toward an informed conversation with your clinician.
To understand where the science stands today, it helps to trace where the uncertainty originated. The landmark Women's Health Initiative (WHI) trial, published in 2002, prompted widespread alarm and a dramatic drop in MHT use. However, subsequent re-analyses revealed that the original findings were heavily influenced by the age and health status of participants, many of whom were well past menopause. The picture that has emerged since is considerably more nuanced. For a broader grounding in how hormones shift during this transition, see our overview of hormonal changes from perimenopause through postmenopause.
Myth
The WHI study proved that hormone therapy causes breast cancer and heart disease.
Fact
The WHI findings were more limited and context-dependent than early headlines suggested; risk varies substantially by hormone type, timing, and individual health profile.
The 2002 WHI trial studied a specific combination of oral conjugated equine estrogen plus medroxyprogesterone acetate in women whose average age was 63 — older than the typical menopause onset by roughly a decade. Subsequent re-analyses, including data from the WHI itself, found that younger women initiating MHT closer to menopause did not show the same elevated cardiovascular risks. Breast cancer risk associated with combination estrogen-progestogen therapy is real but modest in absolute terms, and estrogen-only therapy (used in women without a uterus) was actually associated with a reduced risk of breast cancer in some analyses. The science is genuinely complex, not a simple verdict.
Myth
All hormone therapies carry the same risks regardless of how they are taken.
Fact
Delivery method and hormone type meaningfully affect the risk profile; transdermal estrogen, for example, appears to carry a lower clot risk than oral formulations.
Oral estrogen undergoes first-pass metabolism in the liver, which can affect clotting factors and triglyceride levels. Transdermal preparations (patches, gels, sprays) bypass this pathway and are associated with a lower risk of venous thromboembolism (VTE) in observational studies. Similarly, the type of progestogen used alongside estrogen matters: micronized progesterone appears to carry a more favorable cardiovascular and breast risk profile than synthetic progestins such as medroxyprogesterone acetate, though long-term comparative data continue to accumulate. These distinctions are clinically significant and should be part of any MHT discussion.
Myth
Once you start hormone therapy, you have to stay on it forever.
Fact
MHT is not an indefinite commitment; the appropriate duration is determined individually, and many women use it for a defined period to manage the most acute phase of symptoms.
Current guidance generally supports using MHT at the lowest effective dose for the shortest duration appropriate to a woman's goals and risk profile — but this does not mean a fixed short window for everyone. Some women with ongoing vasomotor symptoms or specific indications such as early menopause may benefit from longer use after a careful risk-benefit discussion. There is no universally mandated cut-off. Decisions about when to taper or discontinue should be made collaboratively with a clinician, not based on arbitrary timelines.
Myth
Hormone therapy is only relevant if you have severe hot flashes.
Fact
MHT is used for a range of menopausal symptoms and conditions beyond hot flashes, including genitourinary symptoms, bone density preservation, and sleep disruption.
While vasomotor symptoms (hot flashes and night sweats) are the most frequently cited reason for initiating MHT, they are far from the only indication. Genitourinary syndrome of menopause — which encompasses vaginal dryness, pain during sex, and recurrent urinary tract infections — responds well to low-dose local estrogen, which has minimal systemic absorption. Bone density loss that accelerates after menopause is another recognized indication in appropriate candidates. Sleep disturbance and mood changes related to hormonal fluctuations may also improve with treatment. The scope of potential benefit extends well beyond temperature regulation. For more on the full range of hormonal changes involved, see the role of hormone testing during menopause.
Myth
Natural or bioidentical hormones are inherently safer than conventional hormone therapy.
Fact
The term 'bioidentical' is not a regulated safety classification; compounded preparations in particular lack the standardized testing required of FDA-approved products.
"Bioidentical" refers to hormones that are chemically identical to those produced by the human body, but this structural similarity does not automatically confer a superior safety profile. Some FDA-approved MHT products contain bioidentical hormones (including estradiol and micronized progesterone) and have undergone rigorous testing for purity, potency, and safety. Compounded bioidentical hormone preparations, however, are not subject to the same regulatory oversight, and there is no high-quality evidence that they are safer or more effective than approved alternatives. Major medical societies advise caution regarding unregulated compounded preparations.
What the Evidence Currently Supports
Current clinical guidelines from major bodies — including the Menopause Society (formerly NAMS) and the British Menopause Society — reflect a substantially more favorable view of MHT for appropriately selected women than guidance issued in the years immediately following the WHI. Key areas of established consensus include:
- Vasomotor symptom relief: MHT is consistently identified as the most effective available treatment for hot flashes and night sweats.
- Genitourinary benefits: Low-dose vaginal estrogen is well-supported for genitourinary syndrome of menopause (GSM), including vaginal dryness and discomfort, with a favorable systemic safety profile.
- Bone protection: Estrogen therapy has a documented protective effect on bone density and is recognized as an option for osteoporosis prevention in appropriate candidates.
- Timing matters: The "timing hypothesis" — supported by multiple analyses — suggests that initiating MHT closer to menopause onset (typically within 10 years or before age 60) is associated with more favorable cardiovascular outcomes than starting later.
~80%
Women experiencing vasomotor symptoms
Approximately 80% of women experience hot flashes or night sweats during the menopausal transition, according to estimates cited by the Menopause Society.
~50%
Decline in MHT prescriptions after 2002
Following the initial publication of the WHI trial results in 2002, MHT prescriptions in the US dropped by roughly half within a few years, according to pharmacy data analyses published in subsequent years.
10 years
Timing window for favorable outcomes
The 'timing hypothesis' — supported by multiple re-analyses of WHI and other data — suggests initiating MHT within 10 years of menopause onset is associated with more favorable cardiovascular risk profiles.
For women who are not candidates for or who prefer to avoid hormone therapy, evidence-supported alternatives do exist. Our article on non-hormonal approaches to managing menopause symptoms outlines what the research shows.
Avoid Self-Prescribing or Stopping Abruptly
Hormone therapy — including over-the-counter products marketed for menopause — should not be started, adjusted, or discontinued without clinician guidance. Stopping abruptly after extended use may cause a return of symptoms. If you have concerns about your current regimen, schedule a review with your healthcare provider rather than making changes independently.
Questions Worth Asking Your Healthcare Provider
Because MHT decisions are genuinely individualized, the most productive use of this information is as preparation for a clinical conversation — not as a substitute for one. Consider discussing the following with your provider:
- Am I a candidate for MHT given my personal and family health history?
- Which formulation and delivery route would be most appropriate for my symptoms and risk profile?
- How long should treatment continue, and what monitoring is recommended?
- Are there specific risks — such as prior clot history, estrogen-sensitive cancers, or cardiovascular disease — that change the calculus for me?
If you are newer to understanding this transition, our starting point guide for women new to menopause provides foundational context. Weight changes during midlife — often mistakenly attributed solely to hormones — are addressed in our piece on hormones, weight, and midlife.
This article is for general informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any decisions about hormone therapy or other medical treatments.
The content on this site is for informational purposes only and is not a substitute for professional advice. Always consult a qualified professional for guidance specific to your situation.